Efficacy and safety of azithromycin for uncomplicated typhoid fever: an open label non-comparative study

Indian Pediatr. 2011 Jul;48(7):553-6. doi: 10.1007/s13312-011-0093-y.

Abstract

An open-labelled, non-comparative study was conducted in 117 children aged 2-12 years to evaluate the efficacy and safety of azithromycin (20mg/ kg/day for 6 days) for the treatment of uncomplicated typhoid fever. Of the patients enrolled based on a clinical definition of typhoid fever, 109 (93.1%) completed the study.Mean (SD) of duration of fever at presentation was 9.1(4.5) days. Clinical cure was seen in 102 (93.5%) subjects, while 7 were withdrawn from the study because of clinical deterioration. Mean day of response was 3.45±1.97. BACTEC blood culture was positive for Salmonella typhi in 17/109 (15.5%) and all achieved bacteriological cure. No serious adverse event was observed. Global well being assessed by the investigator and subjects was good in 95% cases which was done at the end of the treatment. Azithromycin was found to be safe and efficacious for the management of uncomplicated typhoid fever.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / therapeutic use*
  • Azithromycin / adverse effects
  • Azithromycin / therapeutic use*
  • Bacteremia / drug therapy
  • Bacteremia / microbiology
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Male
  • Salmonella typhi / drug effects
  • Salmonella typhi / isolation & purification
  • Treatment Outcome
  • Typhoid Fever / drug therapy*
  • Typhoid Fever / microbiology

Substances

  • Anti-Bacterial Agents
  • Azithromycin